Comparing Can-Fite BioPharma (NYSE:CANF) and PaxMedica (NASDAQ:PXMD)

Can-Fite BioPharma (NYSE:CANF) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Profitability

This table compares Can-Fite BioPharma and PaxMedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

Valuation and Earnings

This table compares Can-Fite BioPharma and PaxMedica”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405,000.00	5.42	-$7.63 million	($35.80)	-0.09
PaxMedica	N/A	N/A	-$18.29 million	($6.09)	0.00

Can-Fite BioPharma has higher revenue and earnings than PaxMedica. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Can-Fite BioPharma has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Can-Fite BioPharma and PaxMedica, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	1	2	0	2.67
PaxMedica	0	0	0	0	0.00

Can-Fite BioPharma currently has a consensus target price of $42.50, suggesting a potential upside of 1,168.66%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than PaxMedica.

Summary

Can-Fite BioPharma beats PaxMedica on 9 of the 12 factors compared between the two stocks.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

About PaxMedica

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.